Invasive fungal infections are a major cause of morbidity and mortality in immunocompromised patients, such as subjects with hematological malignancies and patients who underwent to hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT). Fusarium spp. cause a broad spectrum of infections in humans. Immunologically competent hosts show mainly localized skin infections, whereas disseminated fusariosis occurs almost exclusively in immunocompromised patients. Fusarium spp. are resistant to many antifungal agents with equivocal in vitro and in vivo susceptibility to amphotericin B. Voriconazole (VRC) is a triazole shown to be safe, well tolerated, and in vitro effi cacious against Fusarium spp. Although clinical experience is limited, many case reports have shown the effi cacy of VRC in the treatment of fusariosis.
Introduction
Invasive fungal infections are a major cause of mortality from infection in immunocompromised patients with hematological malignancies, hematopoietic stem cell transplantation (HSCT), and solid organ transplantation (SOT) (De Pauw et al 1999; Nucci 2003; Nucci et al 2003) . The introduction of fl uconazole prophylaxis in such patients has led to a shift in the epidemiology of fungal infections with a dramatic reduction of the incidence of candidiasis (Anaissie et al 1986; Boutati and Anaissie 1997; Marr et al 2002) . By contrast, the incidence of mould infections such as aspergillosis and other non-aspergillar fungal infections has increased signifi cantly (Marr et al 2002; Walsh et al 2004) . Among immunocompromised patients, invasive fusariosis is the second most common cause of mould infections after aspergillosis with an increasing incidence (Boutati and Anaissie 1997; Nucci 2003; Nucci et al 2004) .
Fusarium spp. are plant pathogens and soil saprophytes that cause a broad spectrum of infections in humans, including superfi cial (keratitis, onychomycosis), locally invasive, and disseminated infection. Disseminated fusariosis occurs almost exclusively in immunocompromised individuals (Nucci et al 2002; Dignani et al 2004) . Recently, Nucci et al reported the clinical characteristics and prognostic factors of 61 patients with fusariosis after HSCT (54 allogeneic HSCT, 7 autologous HSCT). The reported incidence of fusariosis ranged from 5 infections per 1000 HSCTs in human leucocyte antigen (HLA) matched related transplantations to 20 infections per 1000 HSCTs in HLA mismatched transplantations. The survival rate was 13%, with a median onset of 13 days from the diagnosis, and the single prognostic factor for death by multivariate analysis was persistent neutropenia (Nucci et al 2004) . The incidence of invasive fungal infections is also increasing in SOT ranging between 5% and 20% (Lodato et al 2006) , probably due to the use of more intense immunosuppression regimens to reduce acute allograft rejection. Between 1996 and 2007, 10 cases of fusariosis in patients who underwent SOT were reported in literature. Nine of them were localized whereas one patient experienced disseminated fusariosis. The infection resolved in 9 of these patients. None died from fusariosis (Young and Meyers 1979; Heinz et al 1996; Arney et al 1997; Girardi et al 1999; Linden et al 2000; Sampathkumar et al 2001; Cocuroccia et al 2003; Garbino et al 2004; Lodato et al 2005) . Part of these data are presented in Table 1 .
The incidence of fusariosis and its mortality rate are signifi cantly higher in patients with hematological malignancies and in those with allogeneic HSCT due to more intense immunosuppression and profound and prolonged neutropenia. The genus Fusarium comprises a large number of species (more than 20) and the most common human pathogen is Fusarium solani isolated in approximately half of the reported infections. The remaining cases of human fusariosis are caused by Fusarium oxysporum, Fusarium moniliforme, and Fusarium verticillioides, each of which account for 10%-14% of all infections. Considering the increasing incidence of Fusarium spp. infections, an increased virulence of these species cannot be excluded (Nelson et al 1994; Nucci et al 2003) .
Fusarium spp. manifest an inherent resistance to a multitude of antifungal agents, making the treatment of fusariosis a challenging task especially in severely immunosupressed individuals with hematological malignancies or transplant recipients. In this patient population fusariosis is frequently fatal (Al-Abdely 2003) . Despite its equivocal in vitro susceptibility and treatment failures (Arikan et al 1999) , amphotericin B has remained the drug of choice for the management of disseminated fusariosis (Guarro et al 1995) . 
Treatment of fusariosis
Fusarium spp. can cause local and, most importantly, disseminated infections in immunocompromised patients with involvement of multiple organs including the skin (Figure 1 ).
For the clinician taking care of patients with hematological malignancies disseminated fungal infections constitute one of the most diffi cult challenges. In this patient population Fusarium spp. is an emerging cause of non-Aspergillus mould infection and is associated with high mortality. In 1997 Boutati and Anaissie (Boutati and Anaissie 1997) described 43 patients with hematological malignancies who developed invasive Fusarium spp. infection. Thirteen of these (30%) responded to therapy with amphotericin B deoxycholate (AMBD) or its lipid formulations [liposomal amphotericin B (AmB-L); amphotericin B lipid complex (ABLC)]. The majority (70%) of patients died from the infection while a resolution was only seen in patients who ultimately recovered from cytopenia (Boutati and Anaissie 1997; Kontoyiannis et al 2004) . More recently, 84 cases of Fusarium spp. infection in patients with hematological malignancies were reported (Nucci 2003) . Of them, only 21% were alive 90 days after the diagnosis.
Polyenes
Current therapy for refractory invasive fungal infections caused by less-common moulds remains inadequate. Since fusariosis may mimic aspergillosis in its clinical manifestations, affected patients were usually treated with amphotericin B, an agent with poor activity in vitro against Fusarium spp. (Pfaller et al 2002) , whereas evidence of a good in vivo activity is reported with ABLC (Lodato et al 2006) and AmB-L (Jensen et al 2004; Selleslag 2006) .
Azoles Itraconazole
Itraconazole was demonstrated to exert negligible activity against Fusarium spp. . It has rarely been administered against Fusarium spp. infections with unequivocal results. Additionally it has been demonstrated that amphotericin B and VRC are consistantly more effective than itraconazole against Fusarium isolates (Lewis et al 2005) . Itraconazole has seldom been administered for Fusarium infections with nonunivocal results (Reis et al 2000; Pereiro et al 2001; Cocuroccia et al 2003; Vincent et al 2003) .
Voriconazole
VRC is an extended-spectrum, synthetic triazole derivative of fl uconazole, whose mechanism of action is inhibition of the cytochrome P450 (CYP)-dependent enzyme 14-α-sterol demethylase, preventing the fungal cell membrane synthesis and causing its disruption Ghannoum and Kuhn 2002; Johnson and Kauffman 2003; Herbrect 2004; Scott and Simpson 2007) .
Intravenous and/or oral VRC is generally well tolerated. Nevertheless, approximately half of all subjects receiving VRC experienced at least one treatment-related adverse event ( In Candida spp. VRC is fungistatic, whereas in fi lamentous organisms it is fungicidal. VRC shows in vitro activity against a variety of yeasts, fi lamentous fungi and dimorphic moulds. Candida spp., Aspergillus spp., Fusarium spp., and Scedosporium spp. are the pathogens against which VRC has been approved for treatment, whereas it has little or no activity against Zygomycetes.
Susceptibility of fi lamentous fungi to VRC was tested by 3 studies ( The effi cacy and safety of VRC for the primary treatment of invasive aspergillosis in immunocompromised patients has been described in randomized, non-blind, multinational trials and in observational studies (Denning et . We found 20 disseminated fusariosis and 14 localized infections: 10 ocular involvements, 2 cutaneous lesions, 1 pneumonia, 1 peritonitis. Hematological disease was the underlying setting in 18 patients, while solid tumor and chronic emphysema affected one patient each. All the patients with disseminated infection were immunodepressed because of chemotherapy, or HSCT, or steroids administration, as shown in Table 1 . The overall response to VRC for disseminated fusariosis was 63% (12/19 evaluable). Treatment with VRC was initiated in 19 patients with the iv loading dose of 6 mg/kg bid, followed by the maintenance dose of 4 mg/kg bid. The switch to the oral treatment (200 mg bid) was made in 18 patients. Only one patient received the oral formulation of VRC from the start. For localized infections, VRC was administered iv to 5 patients, eventually followed by oral administration for long-term maintenance. Topical VRC preparation could be added. In 6 patients oral voriconazole was administered from the beginning, while 2 patients received only topical formulations. In 3 patients with disseminated fusariosis, combined therapy consisting in voriconazole and AmB-L was administered, while VRC was given as salvage treatment in 4 patients with disseminated fusariosis (data shown in Table 1 ).
Recently, Perfect et al reported a multicenter, open-label, clinical study to assess the effi cacy and safety of VRC for the treatment of less-common, emerging or refractory invasive fungal infections (Perfect et al 2003) . Three-hundred and one immunocompromised patients were studied. The drug was administered iv at recommended dosages for at least 3 days, and the median duration of iv treatment was 18 days (range 1-138 days). Thereafter patients could be switched to oral treatment. The median duration of oral administration was 69 days (range 1-326 days). In the study they treated 11 fusariosis, showing 45% of satisfactory global response with respect to the high mortality rate (70%) for disseminated fusariosis treated with other therapies (Krcmery et al 1997; Boutati and Anaissie; Perfect et al 2003) . These results were consistent with data from previous reports focused on the use of VRC in critically ill patients. They confi rm its good profi le concerning safety and tolerability, with an incidence of treatment-related toxicities, such as visual disturbances and rashes, requiring suspension for 3.5% of patients, but none of the toxicities were severe. Also liver function abnormalities were noted in Ͼ10% of patients, but only 2.4% had their treatment discontinued, confi rming previously reported data (Potoski and Brown 2002) .
Posaconazole
Posaconazole (PSC) is a potent extended spectrum tiazole that has been shown to be highly active against yeasts and moulds, including Fusarium spp. (Espinel-Ingrof et al 2004; Torres et al 2005) . Recently, Raad et al described a clinical experience with PSC utilized for refractory fusariosis or for patients intolerant to conventional antifungal therapy in 21 cases, with an overall response of 48%. This result is comparable with those seen with VRC, and prolonged neutropenia was an unfavorable risk factor of non-response (20% in patients who recovered from myelosuppression versus 67% in patients who did not recover) (Raad et al 2006) . Moreover, 4 cases of ocular infection and 1 case of pneumonia by Fusarium spp. were described, treated and resolved with PSC after failure of treatment with VRC (iv, oral, and topical formulation) and other antifungal drugs (Sponsel et al 2002; Herbrecht et al 2004; Tue et al 2007) .
PSC is administered as an oral suspension with food and this could limit its use in critically ill patients.
These results suggest PSC can be considered an appropriate alternative antifungal therapy to amphotericin B formulation, leading to results similar to those once found with VRC.
Echinocandins
Fusarium spp. are usually resistant to echinocandins by standard susceptibility testing (Spellberg et al 2006) . Instead, a case of fungemia sustained by Fusarium spp. resistant to amphotericin B was resolved with caspofungin at standard doses in a patient with acute myeloid leukemia (Apostolidis et al 2003) . A recent murine model disclosed that caspofungin at 1 mg/kg/day improved survival during active fusariosis, despite lack of reduction in fungal burden (Spellberg et al 2006) , suggesting a potential role in the treatment of human fusariosis.
Future perspectives
The in vitro interaction of itraconazole, amphotericin B and VRC with anidulafungin against Aspergillus spp. and Fusarium spp. was recently evaluated (Philip et al 2005) . 
Voriconazole for fusariosis
Anidulafungin belongs to the echinocandins antifungal drugs class. The data showed that all drug combinations suggested indifference against Fusarium spp., but not antagonism or synergism. A previous study reported a potential synergistic to additive effect of caspofungin in combination with amphotericin B against Fusarium spp. (Dismukes et al 2000) . Also the combination of VRC and micafungin was tested showing a synergistic effect against Fusarium spp. (Heyn et al 2005) , but clinical studies are needed to confi rm these data.
Nystatin is classifi ed among the most effi cient antifungal agents, widely used since 1950s, but insoluble in water. The in vitro activity of polymeric complexes of nystatin was investigated against growth inhibition and spore germination of Fusarium oxysporum. These complexes of nystatin were 3-25 times more active than nystatin against spore germination and were effective inhibitors of mycelial growth (Charvalos et al 2002) . Their use in the clinical setting has not yet been investigated.
Conclusions
Invasive fusariosis is an emerging cause of mould infections in immunocompromised patients, with usually poor prognosis being Fusarium spp. resistant to most available antifungal agents (Nucci 2003) . In vitro susceptibility testing may be the only clue in the choice of the appropriate antifungal agent ( Stanzani et al 2006; Bunya et al 2007) , with a 63% overall response for disseminated fusariosis, while Perfect et al reported a 45% satisfactory global response, with respect to the high mortality rate (70%) for patients treated with other antifungal drugs (Perfect et al 2003) .
PSC is a new potent extended spectrum tiazole that has been shown to be active against Fusarium spp. (Espinel-Ingrof et al 2004; Torres et al 2005; Raad et al 2006) . However, no clinical trials have hitherto compared PSC with VRC or addressed the relative use of these two broad spectrum tiazole agents in the management of fusariosis. Polymeric complexes of nystatin have been investigated against Fusarium oxysporum, but there have been no published clinical trials.
In conclusion, treatment of emerging invasive fungal infections is a major challenge, with no standardized therapy and high mortality rates. VRC seems to be the most promising antifungal agent for the treatment of disseminated fusariosis in immunocompromised subjects, but more clinical evidence is required.
